{
  "id": 8114959,
  "title": "Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock",
  "url": "https://urgent.news/2026/09/17/inhibrx-biosciences-director-jon-kayyem-buys-500-000-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T22:15:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/inhibrx-biosciences-director-jon-kayyem-buys-500000-in-stock-93CH-4906533"
  },
  "original_language": "en",
  "account": null,
  "summary": "Inhibrx Biosciences director Jon Kayyem recently acquired 5,000 shares of the company's common stock, purchasing them for $500,000 at a price of $100 per share on September 16, 2026. Despite the stock currently trading at $104.73, near Kayyem's purchase price, it has declined 6% over the past week. The Insider purchase comes as InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value, with a potential to provide valuable insights to investors seeking comprehensive valuation. In recent news, Inhibrx Biosciences announced promising results from the Phase 2 portion of the HexAgon-HN trial, evaluating its drug INBRX-106 in combination with Keytruda for head and neck cancer, which showed a confirmed overall response rate of 48.3% and a median progression-free survival of 9.6 months, surpassing Keytruda alone. Following these results, H.C. Wainwright reiterated its Buy rating for Inhibrx with a price target of $245.00, while Stifel maintained its Buy rating, setting a price target of $325.00.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}